Baseline characteristics of subjects
| Characteristic . | Median (range or %), n = 37 . |
|---|---|
| Age (y) | 74 (60-94) |
| Sex, female/male | 21/16 |
| Race, white/black or non-white | 33/4 |
| Prior MDS diagnosis | 19 (51%) |
| Baseline: | |
| WBC, ×103/mL | 2.6 (0.6-658) |
| Platelet count, ×103/mL | 53 (6-4000) |
| Peripheral blasts, % | 4 (0-72) |
| Marrow blasts, % | 38 (17-90) |
| Zubrod performance status | |
| 0 | 7 (19%) |
| 1 | 30 (81%) |
| 2 | 0 |
| WHO or FAB classification | |
| AML with multilineage dysplasia | 10 (27%) |
| AML not otherwise specified | 10 (27%) |
| Secondary AML (prior MDS or therapy-related) | 4 (11%) |
| Myelomonocytic leukemia | 4 (11%) |
| AML with maturation | 4 (11%) |
| AML without maturation | 3 (8%) |
| AML with minimal differentiation | 1 (3%) |
| Acute erythroid leukemia | 1 (3%) |
| Cytogenetic abnormalities, 30 (81%) | |
| Isolated del(5q) by FISH | 1 (3%) |
| Isolated del(5q) by MC | 5 (17%) |
| Isolated trisomy 8 by MC, del(5q) by FISH | 1 (3%) |
| Complex | 23 (77%) |
| Characteristic . | Median (range or %), n = 37 . |
|---|---|
| Age (y) | 74 (60-94) |
| Sex, female/male | 21/16 |
| Race, white/black or non-white | 33/4 |
| Prior MDS diagnosis | 19 (51%) |
| Baseline: | |
| WBC, ×103/mL | 2.6 (0.6-658) |
| Platelet count, ×103/mL | 53 (6-4000) |
| Peripheral blasts, % | 4 (0-72) |
| Marrow blasts, % | 38 (17-90) |
| Zubrod performance status | |
| 0 | 7 (19%) |
| 1 | 30 (81%) |
| 2 | 0 |
| WHO or FAB classification | |
| AML with multilineage dysplasia | 10 (27%) |
| AML not otherwise specified | 10 (27%) |
| Secondary AML (prior MDS or therapy-related) | 4 (11%) |
| Myelomonocytic leukemia | 4 (11%) |
| AML with maturation | 4 (11%) |
| AML without maturation | 3 (8%) |
| AML with minimal differentiation | 1 (3%) |
| Acute erythroid leukemia | 1 (3%) |
| Cytogenetic abnormalities, 30 (81%) | |
| Isolated del(5q) by FISH | 1 (3%) |
| Isolated del(5q) by MC | 5 (17%) |
| Isolated trisomy 8 by MC, del(5q) by FISH | 1 (3%) |
| Complex | 23 (77%) |
WBC indicates white blood cell count; FAB, French-American-British; and MC, metaphase cytogenetics.